Long-Term Response to PD-1 and CTLA-4 Blockade in an SCLC Patient with Negative PD-L1 Expression on Biopsy: A Case Report
Despite recent advances in the availability of new therapeutic agents, small-cell lung cancer (SCLC) remains an aggressive disease with a poor prognosis. While immune checkpoint inhibition has revolutionized the treatment of non-small cell histologies, results in SCLC have shown overall less favorab...
Main Authors: | Marco Cefalì, Francesco Martucci, Patrizia Frösch |
---|---|
Format: | Article |
Language: | English |
Published: |
THE HEALTHBOOK COMPANY LTD.
2023-03-01
|
Series: | healthbook TIMES. Oncology Hematology |
Online Access: | https://doi.org/10.36000/hbT.OH.2023.15.099 |
Similar Items
-
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
by: Hiroaki Kanemura, MD, MPH, et al.
Published: (2022-08-01) -
PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
by: Ilaria Porcellato, et al.
Published: (2021-07-01) -
Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01) -
PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer
by: Sandra Bufe, et al.
Published: (2022-10-01) -
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4<sup>+</sup> T Cells
by: Reem Saleh, et al.
Published: (2019-10-01)